KBC Group NV Reduces Stake in IQVIA Holdings Inc. (NYSE:IQV)

KBC Group NV reduced its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.0% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 603,752 shares of the medical research company's stock after selling 12,547 shares during the period. KBC Group NV owned 0.34% of IQVIA worth $106,441,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Brighton Jones LLC boosted its position in shares of IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after buying an additional 2,537 shares during the period. New York Life Investment Management LLC grew its holdings in shares of IQVIA by 0.4% during the 4th quarter. New York Life Investment Management LLC now owns 23,086 shares of the medical research company's stock valued at $4,537,000 after acquiring an additional 81 shares in the last quarter. Proficio Capital Partners LLC bought a new stake in IQVIA in the fourth quarter worth $29,091,000. Bruni J V & Co. Co. bought a new stake in IQVIA in the fourth quarter worth $13,304,000. Finally, Mutual of America Capital Management LLC lifted its position in IQVIA by 49.8% during the 4th quarter. Mutual of America Capital Management LLC now owns 32,030 shares of the medical research company's stock worth $6,294,000 after acquiring an additional 10,655 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Up 3.4%

Shares of IQV stock traded up $5.36 during trading hours on Tuesday, hitting $162.95. 875,987 shares of the company's stock traded hands, compared to its average volume of 1,646,339. The stock's 50 day simple moving average is $149.58 and its 200 day simple moving average is $173.88. The stock has a market cap of $28.19 billion, a PE ratio of 22.17, a price-to-earnings-growth ratio of 1.75 and a beta of 1.28. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 2.19.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The business had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. During the same quarter last year, the firm earned $2.54 earnings per share. IQVIA's quarterly revenue was up 2.5% on a year-over-year basis. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on IQV. UBS Group cut their price objective on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Hsbc Global Res cut shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, Mizuho reduced their price objective on shares of IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a research note on Thursday, May 15th. Eight equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IQVIA has an average rating of "Moderate Buy" and a consensus target price of $226.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.